Maxim Group analyst Jason Kolbert came out today with an update on IsoRay, Inc. (NYSE MKT:ISR), after the company released it’s fiscal second-quarter results this morning.
Maxim’s healthcare analyst Jason Kolbert weighed in today with his thoughts on IsoRay Inc (NYSE:ISR), as the company announced that researchers at the University of Pittsburgh School …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a Buy rating on IsoRay, Inc. (ISR) and increased his price target to $5.
